Tioptropium significantly reduced CID risk and delayed time to first clinically important deterioration

WEDNESDAY, May 8, 2024 (HealthDay News) -- For patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), Tiotropium reduces clinically important deterioration (CID), according to a study published in the February issue of Respiratory Medicine.

Fan Wu, from The First Affiliated Hospital of Guangzhou Medical University in China, and colleagues conducted a post-hoc analysis of the 24-month Tie-COPD study comparing 18 μg Tiotropium to placebo for mild-to-moderate COPD. A decrease of ≥100 mL in trough forced expiratory volume in one second, an increase of ≥2 units in COPD Assessment Test (CAT) score, or moderate-to-severe exacerbation was used to define CID.

The full analysis set included 771 patients. The researchers found that 83.4 percent of patients experienced at least one CID event. Compared with placebo, Tiotropium significantly reduced CID risk and delayed the time to first CID (adjusted hazard ratio, 0.58). In various subgroups, including patients with a CAT score <10, modified Medical Research Council score <2, and mild COPD, significant reductions in CID risk were also observed.

"These findings emphasize the efficacy of Tiotropium in patients with mild disease from the perspective of reducing composite CID," the authors write.

The study was partly supported by an investigator-initiated study program by Boehringer Ingelheim.

Abstract/Full Text (subscription or payment may be required)